Alecensa Gains FDA Approval for ALK-Positive Lung Cancer
Alecensa is now approved as a new option for people with ALK‑positive NSCLC who progress on or are intolerant to crizotinib.
Alectinib (Alecensa) received accelerated FDA approval for metastatic ALK‑positive NSCLC patients who progressed on crizotinib, based on objective response rates (ORR) from two phase II trials.
This approval expands treatment choices for patients with ALK‑positive NSCLC who have limited options after crizotinib failure.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT